Prenalterol

Prenalterol
Clinical data
Trade namesHyprenan
Other namesCGP-7760B; CGP-7760/B; H-133/22; IHP
Routes of
administration		Oral, IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 4-{[(2S)-2-hydroxy-3-(isopropylamino)propyl]oxy}phenol
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.055.246 Edit this at Wikidata
Chemical and physical data
FormulaC12H19NO3
Molar mass225.288 g·mol−1
3D model (JSmol)
  • O(c1ccc(O)cc1)C[C@@H](O)CNC(C)C
  • InChI=1S/C12H19NO3/c1-9(2)13-7-11(15)8-16-12-5-3-10(14)4-6-12/h3-6,9,11,13-15H,7-8H2,1-2H3/t11-/m0/s1 checkY
  • Key:ADUKCCWBEDSMEB-NSHDSACASA-N checkY
 ☒NcheckY (what is this?)  (verify)

Prenalterol, sold under the brand name Hyprenan, is a sympathomimetic agent and cardiac stimulant which acts as a β1-adrenergic receptor partial agonist and is used in the treatment of heart failure.[1][2][3][4][5] It has selectivity for the β1-adrenergic receptor.[1][2][3][4] Its partial agonist activity or intrinsic sympathomimetic activity is about 60%.[6] It is said to have much greater impact on myocardial contractility than on heart rate.[4] The drug has been marketed in Denmark, Norway, and Sweden.[2]

  1. ^ a b Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 1014. ISBN 978-1-4757-2085-3. Retrieved 2024-08-29.
  2. ^ a b c Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Index nominum. Medpharm Scientific Publishers. p. 873. ISBN 978-3-88763-075-1. Retrieved 29 August 2024.
  3. ^ a b Morton IK, Hall JM (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 231. ISBN 978-94-011-4439-1. Retrieved 2024-08-29.
  4. ^ a b c Kendall MJ, Goodfellow RM, Westerling S (June 1982). "Prenalterol--a new cardioselective inotropic agent". J Clin Hosp Pharm. 7 (2): 107–118. doi:10.1111/j.1365-2710.1982.tb01010.x. PMID 7050180.
  5. ^ Hadfield SE, Slee SJ, Snow HM (1989). "The cardiovascular pharmacology of xamoterol, cicloprolol, prenalterol and pindolol in the anaesthetised dog". British Journal of Clinical Pharmacology. 28 (Suppl 1): 78S–81S. doi:10.1111/j.1365-2125.1989.tb03580.x. PMC 1379883. PMID 2572262.
  6. ^ Wirtzfeld A, Klein G, Bibra HV, Sauer E (January 1985). "Prenalterol: a partial beta 1-adrenoceptor agonist or a beta-blocker with intrinsic activity?". Int J Clin Pharmacol Ther Toxicol. 23 (1): 20–27. PMID 2859252.